SCHEMBL3129505

SCHEMBL3129505

CC(C)Oc1cc(N(Cc2cnccn2)c2ccc(C(=O)OC(C)(C)C)cc2)ccc1OC(F)F

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 3/20 0.38
RXRB P28702 1/20 0.36
RXRG P48443 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
GAA P10253 1/20 0.35
PDE4D Q08499 6/20 0.35
PDE4A P27815 5/20 0.35
PDE4B Q07343 5/20 0.35
PDE4C Q08493 5/20 0.35
CCR5 P51681 2/20 0.33
SYK P43405 1/20 0.33
P2RX3 P56373 1/20 0.32
FGFR1 P11362 1/20 0.32
FGFR2 P21802 1/20 0.32
FGFR4 P22455 1/20 0.32
FGFR3 P22607 1/20 0.32
KDR P35968 1/20 0.32
LMNA P02545 1/20 0.32
POLB P06746 1/20 0.32
MAPT P10636 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3131342 0.96 HDAC6 (0.37) RXRAHDAC6GAAPDE4DPDE4A
SCHEMBL3215279 0.93 RXRA (0.35) RXRAHDAC6GAAPDE4DPDE4A
SCHEMBL3193436 0.92 SYK (0.37) HDAC6GAAPDE4DPDE4APDE4B
SCHEMBL3200145 0.92 SYK (0.37) HDAC6GAAPDE4DPDE4APDE4B
SCHEMBL3215299 0.91 HDAC6 (0.37) RXRAHDAC6GAAPDE4DPDE4A
SCHEMBL3132792 0.89 KMT2A (0.36) HDAC6GAAPDE4DPDE4APDE4B
SCHEMBL3126333 0.88 RXRA (0.48) RXRARXRBRXRGGAAPDE4D
SCHEMBL3130954 0.88 PDE4B (0.48) RXRAPDE4DPDE4APDE4BPDE4C
SCHEMBL3214843 0.86 GRM2 (0.41) RXRARXRBRXRGPDE4DPDE4A
SCHEMBL3131421 0.85 SYK (0.45) RXRAGAAPDE4DPDE4APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
WO-2010003084-A2 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS PDE4A, PDE4B, PDE3B RXRA 2856/4885RXRB 2676/4885RXRG 3004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.